2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2021
Adequate short- and long-term pain control with non-opiate analgesics after microdirect laryngoscopy
Bisarya PK, Jiang R, Chao J, Narwani V, Lerner M, Kohli N. Adequate short- and long-term pain control with non-opiate analgesics after microdirect laryngoscopy. American Journal Of Otolaryngology 2021, 43: 103267. PMID: 34695699, DOI: 10.1016/j.amjoto.2021.103267.Peer-Reviewed Original ResearchConceptsAdequate pain controlUse of opioidsPain controlPost-operative painDaily VAS scoresMicrodirect laryngoscopyOpioid medicationsVAS scoresLong-term pain controlSingle-institution prospective studyNon-opiate analgesiaPostoperative pain managementSufficient pain controlPost-operative analgesiaNon-opiate analgesicsVisual analog scaleLong-term painT-testVocal fold lesionsStudent's t-testOpioid analgesiaMost patientsPain managementAnalog scaleProspective study